Member Info for RorkesDrift

I'm just waiting for the performing seal to join in.

I'm heard that - next to lickspittle from Major (he got demoted) Camper serial devils advocate over on TILS was my high point.

I quite like the challenge - if the analysis is robust then it can take it. Last time I did a plan I just did SO and left out TW and the whose thing went ttis up.

Hate to play the school mam (not after getting caught) but its conker not concur.

I can see this becoming payment by results all over again

Not sure he is focused on new or old investors once he had the £48k in bank - his own objectives are long term

Presentations are about putting what they have to offer in shop window - they need big pharma involvement to bring this to life quickly plus structuring expectations for Nasdaq.

Looked a bit bored with the hype around the test - he mentioned he had been trying for a year to get investors on board and you can imagine that's how he measures Hus own success. Seemed touched that investors recognised that we only make money out of the hard work of his staff.

Presentations were more about therapeutics then the test. I think its about trying to get partners on board for that. For the test I think he came across as what will be will be - his mind is on getting value out of a completely new approach asap.

He said June for prototype - why not just relax until then - less than 48 hours later we are all calling for an RNS again. Insert puzzled yellow face

Its looking like Son a are the most likely to get there first. There procedures are more of a FAFF than simple saliva test. Awacta can substitute fairly easily - suspect they are more worried about Awacta appearing than we are of them being first

Was it only Thursday evening we heard prototype ready end of June followed by testing. I think / hope we will get there.

Codejunkie.

The problem isn't what you wrote but there are devious people out there who place fake info to cause either panic or elation.

They tend not to do it on sat morning but they get pulled up pretty quick if it involves something like a friend told me....

Squirrel

Now model a company with £48M in the bank, no revenue, ongoing liabilities, no test but a couple of interesting cancer projects

Model the value of a company with no revenue, no liabilities and £2B in the bank

https://www.nhsx.nhs.uk/blogs/how-we-are-assessing-covid-19-apps/

Wamo or dewamp as you see fit

https://www.abingdonhealth.com/uk-rapid-test-consortium-progress-update/

So its part of the rapid test consortium. ODX are part of it as are Abingdon. Given its giverment run they will probably call it a workflow.

There is also an outfit in Cardiff (private- I checked) who lead the way.

You wait all week for a proper dewamper and then they all appear at once.

I was here looking at covid but was gobsmaked by the pro-dox approach. Low theraoeutic windows on chemo is a real problem - not surprising given they are intended to kill cells.

Since then we have the ups and downs of the test - I think very little has changed but the world seems to think we can move on and the placing with its subsequent profit taking has added some turbulence.

Now with the cash they have sped up two other cancer targets and at some point next year they will have data for BD guys to sign up partners to do the heavy lifting. Not risk free but look at NASDAQ valuations.

Covid test value - pick any value ofveithet £0 or something North of £1B.

Will we eventually get to £50 SP or a £10B company. My feeling is that with a successful cancer phase II in the next two years yes (unsuccessful then no) and a covid test that works we get a fair way towards it. Together well........

That said the point about getting ahead of ourselves is well made but its just enthusiasm. I hope none is buying or selling based on BB posts - if you want to see some spectacular fails look at my portfolio - omnibio my low point. We all recognise the risks

TKevin.

Please leave Kermit and friends out of this. That's my childhood.

Your reference to medical device regulation and pacemakers is odd.

The requirements for a diagnostic device which is a class IIa are different to that for a pacemaker.

Watching Awacta from the side lines I'm struggling to see anything they have done wrong so far - the testing and prototype development looks industry standard and the timelines are ahead - I know we are all frustrated but most start to finish project Gantt charts woukd need months going into years.

Awacta had diagnostics before therapeutics - my take is they struggled to get that industry to adopt the tech.

Can we come back to this on July 1st

https://simpleflying.com/lufthansa-covid-19-tests/

https://www.medicalnewstoday.com/articles/tests-may-miss-more-than-1-in-5-covid-19-cases#Exercise-caution

Others posted something similar but thought this a good summary.

Also highlights that no test will be free of false negatives. I wonder if this opens up opportunity for an alternative - I hear mass spec is one option.

From the son a site

More than 2 billion lateral flow assays are produced each year, including more than 400 million a year each for malaria and HIV tests.

I'm thinking the demand for tests will be the biggest ever - beating both malaria and HIV